LRRC32 and hepatocellular carcinoma: GARP has been reported to be overexpressed in a variety of cancers, among them, breast [19], lung [17], melanoma [18], bone sarcoma [20], gastric [21], colon cancers [9,22], hepatocellular carcinoma [23], papillary thyroid carcinoma [24] and glioblastoma [25].